NEW LISTING ALERT!!!
- Strategic focus on developing and delivering psychedelic medicines to treat Addiction.
- Strong psychedelic drug development pipeline targeting Addiction.
- First mover advantage for clinics in the UK and the EU with 400m people and CAD$25TR GDP.
- The leading research and clinical team in the industry focused on using psychedelics to treat Addiction.
- Multiple scalable revenue streams across drug development and clinical delivery.
Hub On AGORACOM / Corporate Profile / Recent Interview